biotech

WHO seeks 'additional clarifications' from Bharat Biotech for Covaxin to conduct final 'risk-benefit-
Top Stories

Bharat Biotech-

By ANI NEW DELHI: Commenting on the study of the Lancet Infectious Diseases on the effectiveness of COVAXIN (BBV152) against

Scroll to Top